Ready-to-use Dynabeads allows for simultaneous signalling to TCR/CD3 and CD28 for physiological activation and expansion of mouse T cells. This technology out-performs traditional home-brew activation methods (mitogens, ConA, soluble antibodies etc.), and is well documented in the published literature.

Dynabeads allow you to move from mouse studies to clinical research using the same technology platform for activation/expansion.

Product Starting sample Main benefits
Dynabeads Mouse T-Activator CD3/CD28 (0.4 ml)

Dynabeads Mouse T-Activator CD3/CD28 (2 ml)

Dynabeads Mouse T-Activator CD3/CD28 (10 ml)
Mouse spleen or lymph node cells, mouse T cell clones, mouse CD4+ and CD8+ T cell subsets. Artificial antigen-presenting cells, optimized for mouse T cell activation and expansion.

Also includes a new protocol for mouse Treg expansion.

For isolation of T cells prior to T cell activation, we offer a range of Dynabeads for both positive and negative isolation. See the selection guide

References

The references listed below are among the many published papers documenting the performance of the Dynabeads technology for T cell activation and expansion:

  1. He, J el al. (2016) Low-dose interleukin-2 treatment selectively modulates CD4+ T cell subsets in patients with systemic lupus erythematosus. Nature Medicine 22: 991-993.
  2. Yamada, A et al. (2015) Impaired expansion of regulatory T cells in a neonatal thymectomy-induced autoimmune mouse model. Am J Pathology 185: 2886-97.
  3. Keenan, BP et al. (2014) A Listeria vaccine and depletion of T-regulatory cells activate immunity against early stage pancreatic intraepithelial neoplasms and prolong survival of mice. Gastroenterology 146: 1784-1796.
  4. Jhunjhunwala, S et al. (2012) Controlled release formulations of IL-2, TGF-β1 and rapamycin for the induction of regulatory T cells. J Control Release 159: 78-84.
  5. Rapoport, A.P. et al. (2005) Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer. Nat Med 11:1162–1163.
  6. Bonyhadi, M. et al. (2005) In vitro engagement of CD3 and CD28 corrects T cell defects in chronic lymphocytic leukemia. J Immunol 174:2366–2375.
  7. Godfrey, W.R. et al. (2004) In vitro expanded human CD4+CD25+ T regulatory cells can markedly inhibit allogeneic dendritic cell stimulated MLR cultures. Blood 104:453–461.
  8. Coito, S. et al. (2004) Retrovirus-mediated gene transfer in human primary T lymphocytes induces an activation-and transduction/selection-dependent TCRBV repertoire skewing of gene-modified cells. Stem Cells Dev 13:71–81.
  9. Hami, L. et al. (2003) Comparison of a static process and a bioreactor-based process for the GMP manufacture of autologous Xcellerated T cells for clinical trials. BioProcessing Journal Vol. 2 No. 6, November/December 2003.
  10. Berger, C. et al. (2003) CD28 costimulation and immunoaffinity-based selection efficiently generate primary gene-modified T cells for adoptive immunotherapy.Blood 101:476–484.
  11. Levine, B.L. et al. (2002) Adoptive transfer of costimulated CD4+ T cells induces expansion of peripheral T cells and decreases CCR5 expression in HIV infection. Nat Med 8:47–53.